Jeffrey Peterson, MD
Ophthalmology · Honolulu, HINPI 1578889945
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,587 of the $76,552 with a category attached, or 63.5%. 22 manufacturers reported payments, led by Sight Sciences, Inc. at 27.4% of the total. Reporting peaked in 2019 at $30,870 and has fallen 95.1% since, to $1,519 in 2025. Among ophthalmology clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $243.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$21K
- Novartis$21K
- Aerie Pharmaceuticals, Inc.$11K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$10K
- Bausch & Lomb Americas Inc.$4K
- Glaukos Corporation$4K
- plus $5K from 16 others
Across 6 payments — averaging $1476.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$9K
What the payments were for
- Consulting fees$11,53015%
- Speaking & faculty fees$48,58763%
- Travel & lodging$2,5653%
- Food & beverage$13,85018%
- Other$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 49 | $20,982 |
| Novartis | 30 | $20,727 |
| Aerie Pharmaceuticals, Inc. | 21 | $11,048 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 24 | $9,918 |
| Bausch & Lomb Americas Inc. | 17 | $4,416 |
| Glaukos Corporation | 22 | $4,383 |
| Alcon | 44 | $1,930 |
| AbbVie(2 entities) | 49 | $1,288 |
| Johnson & Johnson Surgical Vision, Inc. | 15 | $626 |
| Sun Pharmaceutical Industries Inc. | 9 | $194 |
| Biotissue Holdings Inc. | 1 | $175 |
| NEW World Medical,inc. | 2 | $145 |
| Kala Pharmaceuticals, Inc. | 7 | $145 |
| Dompe US, Inc. | 5 | $137 |
| Tarsus Pharmaceuticals, Inc. | 4 | $103 |
| Oyster Point Pharma, Inc. | 4 | $103 |
| Rxsight Inc | 3 | $75 |
| Eyevance Pharmaceuticals LLC | 3 | $40 |
| Mallinckrodt Hospital Products Inc. | 1 | $39 |
| Shire North American Group Inc | 2 | $35 |
| Harrow Eye, LLC | 1 | $22 |
| Welch Allyn | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COSENTYX$20,219
- OMNI(R) SURGICAL SYSTEM (US)$14,251
- VYZULTA$13,531
- Rocklatan$10,902
- Rhopressa$10,794
- OMNI$5,969
- iStent inject Trabecular Micro-Bypass Stent System$2,536
- iDose$548
- ARGOS$380
- XEN GLAUCOMA TREATMENT SYSTEM$367
- enVista MX60 IOL$300
- iStent inject W$276
- LOTEMAX SM$250
- iDoseTR$193
- iStent Trabecular Micro-Bypass System Model iS3$163
- iAccess Precision Blade$159
- enVista Aspire IOL$150
- XEN$144
- Clareon PanOptix Pro$142
- ReSTOR$141
How this compares
$76,552 in reported general payments places this provider in the 95th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 162 | $113,517 |
| RocklatanNetarsudil Mesylat/Latanoprost | 156 | $95,928 |
| RestasisCyclosporine | 67 | $90,284 |
| LumiganBimatoprost | 86 | $62,588 |
| RhopressaNetarsudil Mesylate | 98 | $57,655 |
| CombiganBrimonidine Tartrate/Timolol | 78 | $41,891 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 105 | $32,610 |
| XiidraLifitegrast | 28 | $31,801 |
| Alphagan PBrimonidine Tartrate | 45 | $16,763 |
| Brimonidine Tartrate | 187 | $16,522 |
| Latanoprost | 820 | $16,294 |
| Loteprednol Etabonate | 66 | $12,907 |
| Brinzolamide | 52 | $10,607 |
| Travoprost | 17 | $8,926 |
| Timolol Maleate | 320 | $7,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,288 | $211,527276 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $11,048 | $153,583254 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $4,416 | $145,318190 claims |
| AlconSimbrinza | $1,930 | $32,610105 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $9,918 | $12,90766 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Honolulu
- Neda NikpoorHonolulu$293K
- Carlton YuenHonolulu$175K
- Alan FaulknerHonolulu$135K
- Michael BennettHonolulu$108K
- Rupa WongHonolulu$72K
- Jon PortisHonolulu$20K
- Tyrie JenkinsHonolulu$19K
- John OlkowskiHonolulu$15K
- Claudia HootenHonolulu$14K
- Kenneth ChangHonolulu$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.